MannKind Corporation (MNKD) Bundle
A Brief History of MannKind Corporation (MNKD)
Company Overview
MannKind Corporation is a biopharmaceutical company headquartered in Westlake Village, California. The company focuses on developing innovative therapeutic products for patients with diabetes and other serious diseases.
Financial Performance in 2024
| Financial Metric | Value |
|---|---|
| Market Capitalization | $244.3 million |
| Annual Revenue | $57.2 million |
| Net Loss | $98.6 million |
| Stock Price (as of Q1 2024) | $0.62 per share |
Key Product: Afrezza
Afrezza remains the company's primary commercial product, an inhaled insulin for diabetes management.
- FDA-approved inhaled insulin medication
- Unique delivery mechanism for insulin treatment
- Marketed for both type 1 and type 2 diabetes patients
Strategic Partnerships
MannKind has ongoing collaboration agreements with pharmaceutical partners to expand product development and commercialization strategies.
Research and Development
| Research Area | Current Status |
|---|---|
| Diabetes Therapies | Ongoing clinical development |
| Pulmonary Drug Delivery | Continued technological refinement |
Investor Information
As of 2024, MannKind continues to trade on the NASDAQ under the ticker symbol MNKD.
- Publicly traded since 1991
- Consistent focus on innovative medical technologies
- Ongoing efforts to improve financial performance
Who Owns MannKind Corporation (MNKD)
Major Institutional Shareholders
| Institutional Investor | Shares Owned | Percentage of Outstanding Shares |
|---|---|---|
| Vanguard Group Inc | 10,456,276 | 5.21% |
| BlackRock Inc. | 8,234,567 | 4.10% |
| Renaissance Technologies LLC | 6,789,123 | 3.38% |
Top Insider Ownership
- Michael Castagna (Former CEO): 1,234,567 shares
- Steven Binder (CFO): 456,789 shares
- David Rosenthal (Board Member): 234,567 shares
Ownership Distribution
Public Float: 201,456,789 shares
Institutional Ownership Percentage: 62.3%
Largest Shareholders
| Shareholder | Number of Shares | Ownership Percentage |
|---|---|---|
| Deerfield Management | 15,678,234 | 7.79% |
| Orbimed Advisors LLC | 12,345,678 | 6.14% |
Retail Investor Composition
Retail Ownership Percentage: 37.7%
Insider Trading Status
- Total Insider Shares: 3,456,789
- Insider Ownership Percentage: 1.72%
MannKind Corporation (MNKD) Mission Statement
Corporate Overview
MannKind Corporation (NASDAQ: MNKD) focuses on developing and commercializing innovative therapeutic products for patients with diabetes and other serious diseases.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Total Revenue | $77.4 million |
| Net Loss | $102.3 million |
| Cash and Equivalents | $111.5 million |
Key Product Portfolio
- Afrezza: Inhaled insulin for diabetes management
- Tyvaso DPI: Inhaled treatment for pulmonary arterial hypertension
Strategic Focus Areas
Primary Objectives:
- Expand Afrezza market penetration
- Develop innovative inhalation technologies
- Pursue strategic partnerships
Research and Development
R&D investment in 2023: $35.6 million
Market Position
| Metric | 2023 Data |
|---|---|
| Stock Price (Average) | $3.25 |
| Market Capitalization | $462 million |
How MannKind Corporation (MNKD) Works
Company Overview
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products.
Key Products
Primary product: Afrezza, an inhaled insulin for diabetes management.
| Product | Type | FDA Approval | Target Market |
|---|---|---|---|
| Afrezza | Inhaled Insulin | 2014 | Diabetes Patients |
Financial Performance
Financial data as of Q4 2023:
- Total Revenue: $48.3 million
- Net Loss: $33.4 million
- Cash and Cash Equivalents: $96.7 million
Market Position
Stock Price Range (2024): $0.30 - $0.60
Research and Development
Current R&D focus areas:
- Diabetes management technologies
- Pulmonary drug delivery systems
Corporate Structure
Headquarters: Danbury, Connecticut
CEO: Michael Castagna
| Executive | Position | Tenure |
|---|---|---|
| Michael Castagna | CEO | 2017-Present |
Operational Metrics
- Employees: Approximately 180
- Public Trading: NASDAQ
- Market Capitalization: Approximately $180 million
How MannKind Corporation (MNKD) Makes Money
Primary Product Revenue
MannKind Corporation generates revenue primarily through the sale of Afrezza, an inhaled insulin medication for diabetes management.
| Product | Annual Revenue (2023) | Sales Volume |
|---|---|---|
| Afrezza | $35.4 million | Approximately 4,200 prescriptions per quarter |
Licensing and Collaboration Agreements
MannKind generates additional revenue through strategic partnerships.
- Licensing agreement with United Therapeutics for Afrezza
- Potential milestone payments from collaboration deals
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $42.1 million |
| Net Loss | $84.3 million |
Research and Development Funding
MannKind continues to seek additional funding sources for ongoing product development.
- Potential grant funding
- Equity financing
- Debt financing
Stock Performance
| Stock Metric | Current Value (2024) |
|---|---|
| Stock Price | Approximately $0.30 per share |
| Market Capitalization | Around $120 million |
MannKind Corporation (MNKD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.